

ENVOY CAPITAL GROUP INC.  
Form 6-K  
November 18, 2011

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**  
Washington, D.C. 20549

**FORM 6-K**

**REPORT OF FOREIGN PRIVATE ISSUER**

**PURSUANT TO RULE 13a-16 OR 15d-16 OF  
THE SECURITIES EXCHANGE ACT OF 1934**

For the month of November 2011

Commission File No. 00-30082

**ENVOY CAPITAL GROUP INC.**

(Translation of registrant's name into English)

**30 St. Patrick Street, Suite 301**

**Toronto, Ontario M5T 3A3**

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F  
**Form 20-F**  **Form 40-F**

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule  
101(b)(1)

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule  
101(b)(7)

Indicate by check mark whether the registrant, by furnishing the information contained in this Form, is also thereby  
furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.  
Yes  No

If "Yes" is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82-

---

**SUBMITTED HEREWITH**

| <b>Exhibits</b> |                                                                                                                                                             |
|-----------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <u>99.1</u>     | <u>News Release dated November 14, 2011 - Envoy Capital announces Merus Labs licensing agreement with Innocoll for surgical adhesion barrier CollaGUARD</u> |
| <u>99.2</u>     | <u>Material Change Report dated November 14, 2011</u>                                                                                                       |
| <u>99.3</u>     | <u>News Release dated November 11, 2011 - Merus Labs And Envoy Capital Enter Into A Definitive Agreement</u>                                                |
| <u>99.4</u>     | <u>Material Change Report dated November 11, 2011</u>                                                                                                       |
| <u>99.5</u>     | <u>Notice of Special Meeting to be held on December 9, 2011, dated November 10, 2011</u>                                                                    |
| <u>99.6</u>     | <u>Joint Management Information Circular dated November 10, 2011</u>                                                                                        |
| <u>99.7</u>     | <u>Form of Proxy</u>                                                                                                                                        |
| <u>99.8</u>     | <u>Letter of Transmittal</u>                                                                                                                                |

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Date: November 14, 2011

**ENVOY CAPITAL GROUP INC.**

*/s/ Andrew Patient*

---

Andrew Patient  
Chief Financial Officer

---